Dear Sir, Knowledgeofthe genetic risk factorsunderlying venous thrombo-embolism (VTE) in the black population remains sparse (1, 2) . Thet wo most common genetic variantst hat predispose to thrombosis (Factor VLeiden and Prothrombin(PT)20210G/A) occur predominantlyinthose of European origin and arerare in othere thnic groups (3) .D espite this, venous thrombosis has a worldwide prevalence, suggesting thatpopulations of non-Europeano riginp ossess previouslyu ncharacterised prothrombotic mutations (2) .Warshawsky et al have reported anovel CtoTmutation occurring oneb asep air( bp) upstreamf rom the known PT20210G/A polymorphismi nf our unrelated African-Americanpatients (4) . Three of these patients hadahistoryofvenous thrombosis or stroke. Thepolymorphism wasabsent in 440 individuals from other US ethnic groups including Caucasians, Hispanics, Asians and Native-Americans. Theworld population distribution and clinicals ignificance of this novelp olymorphism remains unclear.Asthis polymorphism wasrestrictedto African-Americans (most of whom had experienced thromboembolic events), we hypothesised that it might represent acandidate prothrombotic mutation in the UK black population.
We studiedapreviouslyreported group of 125 black subjects (5), 61 with ahistoryofdeep vein thrombosis (DVT) (27 male and 34 female, mean age 56.2 years,S D1 4.6) and 64 healthy controls (9 male and 55 female, mean age 55 years,SD14). All subjects were of African (28.8%) or Afro-Caribbean origin (71.2%) and had negative thrombophilia tests includingg enotypingfor FV Leiden and PT20210A and phenotypic studies for activatedprotein Cresistance, antithrombin,protein C, free protein Sand lupus anticoagulant. Subjects with hereditarythrombophilia(9.1%) were excluded fromthe study.The control subjects had no known historyo fVTE or malignancy. Casesh ad completed astandard course of anticoagulant treatment for objectivelyconfirmed DVTatleast3months previously. Apanel of 50 healthyAsian Indians and 69 healthySouth East Asians were alsos creened fort he presenceo ft his polymorphism.APCRRFLPb ased assayt hat incorporated an invariant digestion site wasdeveloped fordetection of the PT20209C/T polymorphism ( 
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Of the 61 black patients, one C/T heterozygote wasf ound (Fig. 1B) whereas allthe 64 black controls were of the wild type. ADNA sequenceanalysis wassubsequentlyperformed and confirmed heterozygosity for the C/T polymorphism, 1bpupstream from the known 20210G/A mutation at position 20209.Areview of the medicalhistoryofthis patient revealed thathew as a79 year-old Jamaican male with prostatic carcinoma and proximal DVT. The C20209T polymorphism wasnot found in anyofthe 50 healthyAsian Indians or 69 healthySouth East Asians tested. PT20209C/T is anovel polymorphismpreviouslyreported in 4unrelated African Americans butnot in white Americans (4) . We have demonstrated alow prevalence(1.6%) of this polymorphism in 61 black subjectswith venous thrombosis and an absenceofthe polymorphism in healthyblack controls, AsianIndians and SE Asians. The true prevalenceo ft he PT20209C/T polymorphism cannot be defined in asmall case-controlstudy buti tw ould appear to be loweri no ur study population (heterozygosity 0.8%) comparedt oAfrican-Americans( heterozygosity4.9%).Interestingly, in an unpublishedstudy of 503 individualsi nt he UK (unknown ethnicity) referred fors tandard thrombophilia tests, onlyo ne C/Th eterozygotew as detected. Thus,itwould appear that the frequencyofthis mutation in the UK population is not high. The clinicals ignificance of the 20209C/T polymorphisma mong the black population remains unclear and there are as yetinsufficient datatosuggest apossible prothrombotic role.Whetherthe PT20209C/T polymorphism is associated with elevatedprothrombin levels is unknown butthis maybeapossibilitygiven its proximity to PT20210G/A.Further researchisrequired to clarify the prevalenceand significance of the PT20209C/T in the black population. 
Afunctionalserotonin transporter (SLC6A4) polymorphismmodifies the association of smoking anddiabetes with asymptomaticcarotid atherosclerosis
Dear Sir, Serotonin (5-HT), ac rucial mediator of plateleta ctivation, is conveyed into the cells throughamembrane transporter.Thereis a44-bp insertion/deletion polymorphism (long [L] and short[S] allele)inthe promoter region of the SLC6A4 gene,coding for the 5-HTtransporter.The Lallele is associatedwith higher promotera ctivity (1), increased 5-HT uptake in platelets (2) and with higher 5-HT plasma levels (3). Recently,threecase-control studiesdescribed an association of the SLC6A4 polymorphism with coronaryh eartd isease( CHD) and myocardiali nfarction (4-6).Carotid atherosclerosis (CA)measured by ultrasound correlates with existing CHD and is predictiveofcardiacevents in individuals without clinicallye vident disease (7).W ec onsequentlyinvestigated the association of the SLC6A4 polymorphism with asymptomatic CA among participants of the Study of Health in Pomerania(SHIP).
Forthis purpose, atotal of 629 subjects aged45to79years had completed genotyping by PCR and ultrasound investigation of the carotid arteries as previouslyd escribed (8). CA wasd efined as presenceofatherosclerotic plaquesinthe extracranial carotids on eitherside (common, internal,external carotids and carotid bifurcation). Hypertension wasd efineda sas ystolic blood pressure (BP) of ≥ 160 mmHg, ad iastolic BP of ≥ 95 mmHg, or intakeofantihypertensives. Smoking wasdefinedas currentsmokingofatleastone cigarette per day(mean daily consumption: 13.4 ± 8.8 cigarettes),diabetesasself-reportedphysiciandiagnosis of diabetes, or serumhaemoglobin A 1C (HbA 1C ) of >7.0%. Non-fasting blood samples were takenand lipids and HbA 1C were determinedaccording to standard procedures.Data were analyzed using ANOVAand logistic regression. Gene-to-
